斯瑞新材(688102.SH):累計獲得政府補助共1460.78萬元
格隆匯7月1日丨斯瑞新材(688102.SH)公佈,公司及全資子公司陝西斯瑞扶風先進銅合金有限公司、西安斯瑞先進銅合金科技有限公司、陝西斯瑞精密鑄鍛有限公司、陝西盤環科技發展有限公司,及控股子公司蘇州斯瑞未來新材料技術有限公司自2022年3月31日至2022年7月1日累計獲得政府補助款項人民幣1460.78萬元,其中,與收益相關的政府補助為人民幣774.78萬元,與資產相關的政府補助為人民幣686萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.